Video 20 Apr 2017

Interview with Anders Vinther on medicines & vaccines shortages

Read more
Press release 17 Apr 2017

Progress report on biopharmaceutical industry contributions to the global fight against Neglected Tropical Diseases (NTDs)

109 active R&D projects for NTDs, of which over 90% are collaborative involving over 50 universities, non-governmental organizations and public and private sector institutes. Promising NTD pipeline with 7 compounds targeting American Trypanosomiasis (Chagas disease), dengue, Human African trypanosomiasis (sleeping sickness), lymphatic filariasis, rabies, and trachoma. The biopharmaceutical industry continues to deliver on its 2012...

Read more
Infographic 11 Apr 2017

Doing our part: Comprehensive efforts to fight Neglected Tropical Diseases (NTDs)

Read more
Report 11 Apr 2017

Doing our part: Innovating to fight Neglected Tropical Diseases

Read more
Expert insight 7 Apr 2017

΄Angkor Wat΄ for Kantha Bopha

The name Kantha Bopha is well known in Switzerland. Beat Richner, pediatrician, cello player, and savvy fundraiser, has been working there tirelessly for over 20 years on his life-long project. He had already worked at the Children’s Hospital in Phnom Penh in the early 70’s, then the terror of the Khmer Rouge’s reign forced him...

Read more
Expert insight 4 Apr 2017

Pioneering work for animal welfare

Animal testing has been and will remain controversial. Whereas most people accept the need to test new medicines or vaccines on laboratory animals before they are authorized for human use, it is also widely accepted that there is a need to strike the right and careful balance between expected benefit for patients and research on...

Read more
Report 4 Apr 2017

R&D Pipeline for EBOLA

Read more
Report 4 Apr 2017

R&D Pipeline for MALARIA

Read more
Statement 27 Mar 2017

Delivered at the 21st WHO Expert Committee on the Selection and Use of Essential Medicines

By Brendan Shaw, IFPMA Assistant Director General Thank you for the opportunity to make this statement today on behalf of the research-based pharmaceutical companies and associations across the globe. It seems appropriate that today, forty years after the creation of the World Health Organization’s essential medicines list (EML) and in the midst of the Sustainable...

Read more
Report 24 Mar 2017

Taking a Leap Toward Global Supply Chain Efficiency – Part II

Read more
Expert insight 20 Mar 2017

Dispelling myths from facts in the drugs cost conundrum

It is quite amazing how health policy discussions are often held in a distorted and simplified manner. Nowhere does this apply more than in discussions on drugs and the pharmaceutical industry. Although a large portion of public health spending is accounted for by hospitals, doctors, other health care personnel, and services, the pharmaceutical industry is...

Read more
Expert insight 16 Mar 2017

Encouraging antimicrobial research: Incentives needed

(This is a re-posting that was first published on Monday 13 March in the Basler Zeitung) ‘Vets are expensive. Antibiotics are cheap.’ In a nutshell, this was a quote extracted from last week’s BBC report of the growing global problem of antimicrobial resistance highlighting the plight of overuse of antibiotics on farms in China. The BBC...

Read more